

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### VOLUNTARY ANNOUNCEMENT

#### ACQUISITION OF EQUITY INTEREST IN RECOMGEN BIOTECH

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group has completed its acquisition of 100% interests in Zhuhai Zhifan Enterprise Management Consultancy Centre (Limited Partnership)\* (珠海至凡企業管理諮詢中心(有限合夥)) (“**Zhuhai Zhifan**”), a limited partnership established in the People’s Republic of China (the “**PRC**”), from independent third parties (the “**Acquisition**”).

Zhuhai Zhifan currently holds registered capital of Guangzhou Recomgen Biotech Co., Ltd.\* (廣州銘康生物工程有限有限公司) (“**Recomgen Biotech**”), a limited liability company established in the PRC, in the amount of RMB94,452,874 (among which RMB32,866,514 has not been paid up), representing approximately 51% of the total registered capital of Recomgen Biotech as at the date of this announcement. According to the relevant agreements, the Group will, through Zhuhai Zhifan, inject funds into Recomgen Biotech in the amount of RMB154,472,616 (among which RMB32,866,514 shall be applied to pay up the unpaid registered capital and the remaining RMB121,606,102 shall be applied as capital reserve). Zhuhai Zhifan’s principal activity is its investment in Recomgen Biotech.

Mingfule (銘復樂) (recombinant human TNK tissue-type plasminogen activator for injection) (the “**Product**”) is a third-generation specific thrombolytic drug independently developed by Recomgen Biotech with intellectual property rights. It was launched in China in 2015 for the treatment of thrombolysis in patients with acute myocardial infarction within 6 hours of onset. Its indication for thrombolysis in cerebral infarction was approved for clinical trial in 2017 with Phase III clinical trial (TRACE II) initiated in 2021. As of 28 January 2022, 61 research centres have been initiated with 1,362 patients enrolled.

Established in 2000, Recomgen Biotech is a biotechnology company engaged in R&D, production and sales of biological drugs. The technical team of Recomgen Biotech has extensive experience in R&D, production and quality management of new biological drugs, especially techniques in animal cell culture and protein isolation, built with a world-class GMP certified production facility and an industrialized production line for continuous mammalian cell culture.

The Company believes that the Product has a promising commercial potential. The Acquisition will further strengthen the Group's product portfolio and provide a new growth driver.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**Cai Dongchen**  
*Chairman*

Hong Kong, 8 February 2022

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Professor WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.*

*\* For identification purpose only*